Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial
Rosemary A Hannon, Glen Clack, Martin Rimmer, Alan Swaisland, J Andrew Lockton, Richard D Finkelman, Richard EastellVolume:
25
Year:
2010
Language:
english
Pages:
9
DOI:
10.1359/jbmr.090830
File:
PDF, 243 KB
english, 2010